Frankly speaking, the fundamentals at this point in time just aren't that red hot. Management just gave midpoint guidance to $2.25 in non-GAAP earnings for 2013 as compared with $2.19 in 2012. At $27.50, Pfizer now fetches about 12.2 times forward earnings. It's not a huge multiple to be sure but still for years and years the company was selling at multiples of 8 and 9.
AAPL is now selling for just a 10 multiple of forward earnings and if AAPL's multiple is merely 10, then by no means is Pfizer cheap at 12.2 times the 2013 expectation. The stock has risen by 18% since mid-November and in markets where the stock isn't coming off of crash lows, this is about as much as the company moves up in a three-month period.
In theory the risk may be unlimited but in actual fact, it is quite limited and quite small here in the $27.50 area with an RSI reading of 75 when I put in the order.